Kiniksa Pharmaceuticals, Ltd.

KNSA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$90.77-1.60%

2026-11-02

Financials

Valuation Metrics

Kiniksa Pharmaceuticals, Ltd.'s Market Cap is $6.98B. At end of 2025 it was $3.06B. Ranked #1072 of 3,116 in US market (top 34%), #347 of 1,472 on NASDAQ (top 24%), #56 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$6.98B	US#1,072/3,116 Sec#56/265
Revenue	$946M	US#1,893/3,116 Sec#55/265
Net Income	$110M	US#1,577/3,116 Sec#53/265
Total Assets	$983M	US#2,479/3,116 Sec#104/265
Net Assets	$710M	US#1,986/3,116 Sec#85/265
Value
P/E	63.73x	US#1,996/3,116 Sec#59/265
P/B	9.83x	US#2,632/3,116 Sec#195/265
PEG	0.31x	US#447/3,116 Sec#15/265
P/S	7.38x	US#2,587/3,116 Sec#101/265
EV/EBITDA	48.11x	US#2,357/3,116 Sec#72/265
FCF Yield	2.82%	US#1,894/3,116 Sec#62/265
Profitability
ROE	15.43%	US#860/3,116 Sec#39/265
ROA	11.14%	US#404/3,116 Sec#31/265
Op. Margin	13.79%	US#1,274/3,116 Sec#54/265
Revenue Growth	58.19%	US#182/3,116 Sec#43/265
Earnings Growth	205.05%	US#150/3,116 Sec#9/265
Financial Health
Debt Ratio	38.45%	US#435/3,116 Sec#124/265
Total Debt	$8M	US#2,851/3,116 Sec#206/265
FCF	$197M	US#1,391/3,116 Sec#46/265
Cash	$82M	US#2,333/3,116 Sec#188/265
Current Ratio	3.91x	US#584/3,116 Sec#163/265
Net Debt/EBITDA	-0.51x	US#391/3,116 Sec#24/265
Performance
1Y Return	145.24%	US#61/3,116 Sec#21/265
1M Return	19.76%	US#89/3,116 Sec#9/265
From 52W High	-7.83%	US#84/3,116 Sec#7/265
1Y MDD	-21.12%	US#717/3,116 Sec#23/265
Trading
Volume	880,608 shares	US#1,220/3,116 Sec#115/265
Trading Value	$81M	US#738/3,116 Sec#38/265
Per Share
EPS	$1.42	US#1,533/3,116 Sec#43/265
BPS	$9.23	US#1,890/3,116 Sec#75/265